Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 9579654, 10 pages
http://dx.doi.org/10.1155/2016/9579654
Review Article

A Case Based Approach to Clinical Genetics of Thoracic Aortic Aneurysm/Dissection

1Department of Experimental and Clinical Medicine, Section of Critical Medical Care and Medical Specialities, DENOTHE Center, University of Florence, Florence 50134, Italy
2Department of Heart and Vessels, Marfan Syndrome and Related Disorders Regional Referral Center, Careggi Hospital, Florence 50134, Italy
3Cardiology Service, CMSR Veneto Medica, Altavilla Vicentina, Vicenza 36077, Italy
4S. Maria agli Ulivi Center, Fondazione Don Carlo Gnocchi, Onlus, IRCCS, Florence 50023, Italy

Received 21 December 2015; Revised 30 March 2016; Accepted 19 April 2016

Academic Editor: Peter J. Oefner

Copyright © 2016 Betti Giusti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Roman, R. B. Devereux, R. Kramer-Fox, and J. O'Loughlin, “Two-dimensional echocardiographic aortic root dimensions in normal children and adults,” The American Journal of Cardiology, vol. 64, no. 8, pp. 507–512, 1989. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Olsson, S. Thelin, E. Ståhle, A. Ekbom, and F. Granath, “Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002,” Circulation, vol. 114, no. 24, pp. 2611–2618, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. R. Keramati, A. Sadeghpour, M. M. Farahani, G. Chandok, and A. Mani, “The non-syndromic familial thoracic aortic aneurysms and dissections maps to 15q21 locus,” BMC Medical Genetics, vol. 11, no. 1, article 143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Pomianowski and J. A. Elefteriades, “The genetics and genomics of thoracic aortic disease,” Annals of Cardiothoracic Surgery, vol. 2, pp. 271–279, 2013. View at Google Scholar
  5. E. Gillis, L. Van Laer, and B. L. Loeys, “Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-β signaling and vascular smooth muscle cell contractility,” Circulation Research, vol. 113, no. 3, pp. 327–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Olsson, F. Granath, and E. Ståhle, “Family history, comorbidity and risk of thoracic aortic disease: a population-based case-control study,” Heart, vol. 99, no. 14, pp. 1030–1033, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Albornoz, M. A. Coady, M. Roberts et al., “Familial thoracic aortic aneurysms and dissections-incidence, modes of inheritance, and phenotypic patterns,” Annals of Thoracic Surgery, vol. 82, no. 4, pp. 1400–1405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. R. Brown, R. K. Greenberg, S. Wong et al., “Family history of aortic disease predicts disease patterns and progression and is a significant influence on management strategies for patients and their relatives,” Journal of Vascular Surgery, vol. 58, no. 3, pp. 573–581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Elefteriades and P. Pomianowski, “Practical genetics of thoracic aortic aneurysm,” Progress in Cardiovascular Diseases, vol. 56, no. 1, pp. 57–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. R. O. Bonow, B. A. Carabello, K. Chatterjee et al., “American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” Journal of the American College of Cardiology, vol. 52, pp. e1–e142, 2008. View at Google Scholar
  11. B. L. Loeys, H. C. Dietz, A. C. Braverman et al., “The revised Ghent nosology for the Marfan syndrome,” Journal of Medical Genetics, vol. 47, no. 7, pp. 476–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Evangelista, F. A. Flachskampf, R. Erbel et al., “Echocardiography in aortic diseases: EAE recommendations for clinical practice,” European Journal of Echocardiography, vol. 11, no. 8, pp. 645–658, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Cecconi, S. Nistri, A. Quarti et al., “Aortic dilatation in patients with bicuspid aortic valve,” Journal of Cardiovascular Medicine, vol. 7, no. 1, pp. 11–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Loscalzo, D. L. M. Goh, B. Loeys, K. C. Kent, P. J. Spevak, and H. C. Dietz, “Familial thoracic aortic dilation and bicommissural aortic valve: a prospective analysis of natural history and inheritance,” American Journal of Medical Genetics, Part A, vol. 143, no. 17, pp. 1960–1967, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. F. Hiratzka, G. L. Bakris, J. A. Beckman et al., “American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American College of Radiology; American Stroke Association; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of Thoracic Surgeons; Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine,” Journal of the American College of Cardiology, vol. 55, no. 14, pp. e27–e129, 2010. View at Publisher · View at Google Scholar
  16. E. D. Burman, J. Keegan, and P. J. Kilner, “Aortic root measurement by cardiovascular magnetic resonance: specification of planes and lines of measurement and corresponding normal values,” Circulation. Cardiovascular Imaging, vol. 1, no. 2, pp. 104–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Vahanian, O. Alfieri, F. Andreotti et al., “Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),” European Journal of Cardio-thoracic Surgery, vol. 42, no. 4, pp. S1–S44, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Shores, K. R. Berger, E. A. Murphy, and R. E. Pyeritz, “Progression of aortic dilatation and the benefit of long-term β- adrenergic blockade in Marfan's syndrome,” The New England Journal of Medicine, vol. 330, no. 19, pp. 1335–1341, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Ladouceur, C. Fermanian, J.-M. Lupoglazoff et al., “Effect of beta-blockade on ascending aortic dilatation in children with the marfan syndrome,” American Journal of Cardiology, vol. 99, no. 3, pp. 406–409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Genoni, M. Paul, R. Jenni, K. Graves, B. Seifert, and M. Turina, “Chronic β-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection,” European Journal of Cardio-Thoracic Surgery, vol. 19, no. 5, pp. 606–610, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. A. Ahimastos, A. Aggarwal, K. M. D'Orsa et al., “Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial,” The Journal of the American Medical Association, vol. 298, no. 13, pp. 1539–1547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. B. S. Brooke, J. P. Habashi, D. P. Judge, N. Patel, B. Loeys, and H. C. Dietz III, “Angiotensin II blockade and aortic-root dilation in Marfan's syndrome,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2787–2795, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Diehm, G. Becker, B. Katzen, J. Benenati, M. Kovacs, and F. Dick, “Statins are associated with decreased mortality in abdominal, but not in thoracic aortic aneurysm patients undergoing endovascular repair: propensity score-adjusted analysis,” Vasa—Journal of Vascular Diseases, vol. 37, no. 3, pp. 241–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Jondeau, D. Detaint, F. Tubach et al., “Aortic event rate in the Marfan population: a cohort study,” Circulation, vol. 125, no. 2, pp. 226–232, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. J. P. Habashi, J. J. Doyle, T. M. Holm et al., “Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism,” Science, vol. 332, no. 6027, pp. 361–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. G. C. Mueller, L. Stierle, V. Stark et al., “Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome,” Heart, vol. 100, no. 3, pp. 214–218, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Groenink, A. W. Den Hartog, R. Franken et al., “Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial,” European Heart Journal, vol. 34, no. 45, pp. 3491–3500, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. V. Lacro, H. C. Dietz, L. A. Sleeper et al., “Atenolol versus losartan in children and young adults with Marfan's syndrome,” The New England Journal of Medicine, vol. 371, pp. 2061–2071, 2014. View at Publisher · View at Google Scholar
  29. O. Milleron, F. Arnoult, J. Ropers et al., “Marfan sartan: a randomized, double-blind, placebo-controlled trial,” European Heart Journal, vol. 36, no. 32, pp. 2160–2166, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Forteza, A. Evangelista, V. Sánchez et al., “Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial,” European Heart Journal, vol. 37, no. 12, pp. 978–985, 2016. View at Publisher · View at Google Scholar
  31. J. R. Cook, N. P. Clayton, L. Carta et al., “Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 4, pp. 911–917, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Franken, A. W. Den Hartog, T. Radonic et al., “Beneficial outcome of losartan therapy depends on type of FBN1 mutation in marfan syndrome,” Circulation: Cardiovascular Genetics, vol. 8, no. 2, pp. 383–388, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Pitcher, J. Emberson, R. V. Lacro et al., “Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data,” American Heart Journal, vol. 169, no. 5, pp. 605–612, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. R. M. Radke and H. Baumgartner, “Diagnosis and treatment of Marfan syndrome: an update,” Heart, vol. 100, no. 17, pp. 1382–1391, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Boodhwani, G. Andelfinger, J. Leipsic et al., “Canadian Cardiovascular Society position statement on the management of thoracic aortic disease,” Canadian Journal of Cardiology, vol. 30, no. 6, pp. 577–589, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Pepe, B. Giusti, M. Attanasio et al., “Major involvement of the cardiovascular system in patients affected by Marfan syndrome: novel mutations in fibrillin 1 gene,” Journal of Molecular and Cellular Cardiology, vol. 29, no. 7, pp. 1877–1884, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Pepe, B. Giusti, L. Evangelisti et al., “Fibrillin-1 (FBN1) gene frameshift mutations in Marfan patients: genotype-phenotype correlation,” Clinical Genetics, vol. 59, no. 6, pp. 444–450, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Liu, I. Schrijver, T. Brenn, H. Furthmayr, and U. Francke, “Multi-exon deletions of the FBN1 gene in Marfan syndrome,” BMC Medical Genetics, vol. 2, article 11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Mátyás, S. Alonso, A. Patrignani et al., “Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome,” Human Genetics, vol. 122, no. 1, pp. 23–32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. K. K. Singh, D. Elligsen, R. Liersch et al., “Multi-exon out of frame deletion of the FBN1 gene leading to a severe juvenile onset cardiovascular phenotype in Marfan syndrome,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 2, pp. 352–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. L. V. Furtado, W. Wooderchak-Donahue, A. F. Rope et al., “Characterization of large genomic deletions in the FBN1 gene using multiplex ligation-dependent probe amplification,” BMC Medical Genetics, vol. 12, article 119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Hilhorst-Hofstee, B. C. J. Hamel, J. B. M. Verheij et al., “The clinical spectrum of complete FBN1 allele deletions,” European Journal of Human Genetics, vol. 19, no. 3, pp. 247–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Rantamäki, I. Kaitila, A.-C. Syvänen, M. Lukka, and L. Peltonen, “Recurrence of Marfan syndrome as a result of parental germ-line mosaicism for an FBN1 mutation,” American Journal of Human Genetics, vol. 64, no. 4, pp. 993–1001, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Collod-Béroud, M. Lackmy-Port-Lys, G. Jondeau et al., “Demonstration of the recurrence of Marfan-like skeletal and cardiovascular manifestations due to germline mosaicism for an FBN1 mutation,” American Journal of Human Genetics, vol. 65, no. 3, pp. 917–921, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Tekin, F. B. Cengiz, E. Ayberkin et al., “Familial neonatal Marfan syndrome due to parental mosaicism of a missense mutation in the FBN1 gene,” American Journal of Medical Genetics Part A, vol. 143, no. 8, pp. 875–880, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Šípek Jr., L. Grodecká, A. Baxová et al., “Novel FBN1 gene mutation and maternal germinal mosaicism as the cause of neonatal form of Marfan syndrome,” American Journal of Medical Genetics, Part A, vol. 164, no. 6, pp. 1559–1564, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Watanabe, H. Sakai, A. Nishimura et al., “Paternal somatic mosaicism of a TGFBR2 mutation transmitting to an affected son with Loeys-Dietz syndrome,” American Journal of Medical Genetics, Part A, vol. 146, no. 23, pp. 3070–3074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. R. A. Montgomery, M. T. Geraghty, E. Bull et al., “Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome,” The American Journal of Human Genetics, vol. 63, no. 6, pp. 1703–1711, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. C.-P. Chen, S.-P. Lin, Y.-N. Su, S.-R. Chern, J.-W. Su, and W. Wang, “Prenatal diagnosis of recurrent autosomal dominant osteogenesis imperfecta associated with unaffected parents and paternal gonadal mosaicism,” Taiwanese Journal of Obstetrics and Gynecology, vol. 52, no. 1, pp. 106–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. Lund, A. C. Nicholls, M. Schwartz, and F. Skovby, “Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/IV,” Acta Paediatrica, International Journal of Paediatrics, vol. 86, no. 7, pp. 711–718, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Raghunath, K. Mackay, R. Dalgleish, and B. Steinmann, “Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation,” European Journal of Pediatrics, vol. 154, no. 2, pp. 123–129, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Cannaerts, G. van de Beek, A. Verstraeten, L. Van Laer, and B. Loeys, “TGF-β signalopathies as a paradigm for translational medicine,” European Journal of Medical Genetics, vol. 58, no. 12, pp. 695–703, 2015. View at Publisher · View at Google Scholar
  53. T. J. Bradley, S. C. Bowdin, C. F. Morel, and R. E. Pyeritz, “The expanding clinical spectrum of extracardiovascular and cardiovascular manifestations of heritable thoracic aortic aneurysm and dissection,” Canadian Journal of Cardiology, vol. 32, no. 1, pp. 86–99, 2016. View at Publisher · View at Google Scholar
  54. A. M. Bertoli-Avella, E. Gillis, H. Morisaki et al., “Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections,” Journal of the American College of Cardiology, vol. 65, no. 13, pp. 1324–1336, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Verstraeten, M. Alaerts, L. Van Laer, and B. Loeys, “Marfan syndrome and related disorders: 25 years of gene discovery,” Human Mutation, vol. 37, no. 6, pp. 524–531, 2016. View at Publisher · View at Google Scholar
  56. B. L. Loeys, U. Schwarze, T. Holm et al., “Aneurysm syndromes caused by mutations in the TGF-β receptor,” The New England Journal of Medicine, vol. 355, pp. 788–798, 2006. View at Publisher · View at Google Scholar
  57. M. E. Lindsay, D. Schepers, N. A. Bolar et al., “Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm,” Nature Genetics, vol. 44, no. 8, pp. 922–927, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Matyas, P. Naef, M. Tollens, and K. Oexle, “De novo mutation of the latency-associated peptide domain of TGFB3 in a patient with overgrowth and Loeys-Dietz syndrome features,” American Journal of Medical Genetics, Part A, vol. 164, no. 8, pp. 2141–2143, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. I. M. B. H. Van de Laar, R. A. Oldenburg, G. Pals et al., “Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis,” Nature Genetics, vol. 43, no. 2, pp. 121–126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. D. C. Koboldt, K. M. Steinberg, D. E. Larson, R. K. Wilson, and E. R. Mardis, “XThe next-generation sequencing revolution and its impact on genomics,” Cell, vol. 155, no. 1, pp. 27–38, 2013. View at Publisher · View at Google Scholar · View at Scopus